Mirabegron: all 141 studies that test it

Page 2 of 2. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.

• Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.CompletedNCT02468375Phase 4
• MIrabegron With oveRACtive bLadder Symptoms in mEnStatus unknownNCT02361502Phase 4
• Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young AdultsStatus unknownNCT02354807Phase 2
• Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutationCompletedNCT02311569Phase 2
• Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.Status unknownNCT02279615Phase 4
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive BladderCompletedNCT02211846Phase 1
• Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male SubjectsCompletedNCT02169713Phase 1
• Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy SubjectsCompletedNCT02127034Phase 1
• Ureteral Stent-related Pain and Mirabegron (SPAM) TrialCompletedNCT02095665Phase 4
• A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose LevelsCompletedNCT02010944Phase 1
• Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of TolterodineCompletedNCT01964183Phase 4
• Beta 3 Agonist Treatment in Heart FailureCompletedNCT01876433Phase 2
• A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese SubjectsCompletedNCT01747564Phase 1
• Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese VolunteersCompletedNCT01720212Phase 1
• A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178CompletedNCT01663961Phase 1
• A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178CompletedNCT01651312Phase 1
• A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted ConditionsCompletedNCT01646294Phase 1
• Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01604928Phase 2
• A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy SubjectsCompletedNCT01579461Phase 1
• A Study to Evaluate Cardiovascular Interactions Between Mirabegron and TamsulosinCompletedNCT01489696Phase 1
• To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken TogetherCompletedNCT01478568Phase 1
• A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet FormulationCompletedNCT01478529Phase 1
• A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult VolunteersCompletedNCT01476800Phase 1
• A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy VolunteersCompletedNCT01334905Phase 1
• A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin SimultaneouslyCompletedNCT01297192Phase 1
• A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive PillCompletedNCT01297179Phase 1
• A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and SexCompletedNCT01285596Phase 1
• A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.CompletedNCT01284868Phase 1
• A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research SubjectsCompletedNCT01284309Phase 1
• A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and FemalesCompletedNCT01199523Phase 1
• A Study of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01043666Phase 3
• A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive BladderCompletedNCT00966004Phase 3
• A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly VolunteersCompletedNCT00965926Phase 1
• Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) MirabegronCompletedNCT00940121Phase 1
• Study of the Effect of Food on the Pharmacokinetics of MirabegronCompletedNCT00939757Phase 1
• A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy SubjectsCompletedNCT00856570Phase 1
• A Long-term Study of YM178 in Symptomatic Overactive Bladder PatientsCompletedNCT00840645Phase 3
• Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy VolunteersCompletedNCT00776516Phase 1
• A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal ImpairmentCompletedNCT00750620Phase 1
• A Study of YM178 in Patients With Symptomatic Overactive BladderCompletedNCT00527033Phase 2
• A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)CompletedNCT00337090Phase 2

← Mirabegron overview